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EDITORIAL REVIEW
Periodic paralysis and voltage-gated ion channels
Periodic paralyses are a group of muscle disorders sharing a
common clinical feature consisting of episodic attacks of muscle
weakness due to sarcolemmal membrane depolarization. This
type of muscle weakness may be induced by modifications in blood
potassium levels related to renal or intestinal deficits. The occur-
rence of muscle weakness secondary to changes in blood potas-
sium levels is rare, however, and is only observed in cases of
profound hypokalemia. In contrast, attacks of muscle weakness
dominate the clinical picture in primary periodic paralyses. Pri-
mary periodic paralyses are familial disorders which were sepa-
rated into hypo- and hyperkalemic types, on the basis of the
observed modifications in blood potassium levels during the
attacks. Recent advances in the understanding of the pathophys-
iology of primary periodic paralyses have shown that both hypo-
and hyperkalemic periodic paralysis are caused by mutations in
voltage-gated ion channels, the muscle calcium and sodium
channel, respectively.
The family of voltage-gated ion channels
Electrical excitability of muscle involves changes in sodium and
potassium permeabilities. Under physiological conditions, synap-
tic transmission between nerve and muscle triggers local depolar-
ization at the endplate, leading to the firing of action potentials.
During the rising phase of the action potential, voltage-gated
sodium channels activate rapidly, allowing an influx of sodium and
thus, membrane depolarization. Before the peak of the action
potential, sodium channels start to inactivate, and the membrane
permeability to sodium drops. At the same time, a delayed and
slow activation of voltage-gated potassium channels takes place,
initiating an outward current which hastens membrane repolar-
ization. By a regenerative process, the action potential propagates
along the sarcolemma, invading the depth of the transverse
tubular system, where it activates voltage-gated calcium channels
involved in the excitation-contraction coupling process.
Voltage-gated ion channels are protein complexes composed of
a principal subunit (the a-subunit) that forms the ion pore by
itself, and of auxiliary subunits which influence activation and
inactivation [reviewed in 1—3]. These channels are expressed in a
variety of cells. Their subunit composition and their structure
depend on the cell type. The sodium channel from skeletal muscle
contains a large a-subunit (260 kD) and a non-covalently associ-
ated /3-subunit of approximately 38 kD, similar to the brain
/31-subunit [41. The skeletal calcium channel consists of an
al-subunit associated with transmembrane a2I- and y-subunits
and an intracellular /3-subunit [5, 6].
Purification, molecular cloning and determination of the pri-
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mary structure of the main subunits of the sodium, calcium and
potassium channels demonstrated that they share similar struc-
tural organizations, and are members of a family which probably
evolved from a common ancestral gene. A recently identified
Escherichia coil homologue of an eukaryotic potassium channel
[7] indicates that the structure has been conserved for least 2
billion years, antidating the divergence between prokaryotes and
eukaryotes.
The structure of these channels consists of four homologous
transmembrane domains, each composed of six transmembrane a
helices (Si to S6) (Fig. 1A). The amino- and carboxy-termini and
the linker regions between domains are all located in the cyto-
plasm. Each domain of the potassium channel is encoded by a
separate gene so that the functional channel is a homo- or
hetero-tetramer. The four domains of the sodium and calcium
channels are encoded by a single gene [reviewed in 8]. The ion
channel comprises an intramembrane pore in the center of a
square array defined by the homologous domains. Each domain
contributes to the wall of the pore (Fig. 1B) [reviewed in 9]. The
fourth transmembrane segment in each domain (S4) has a major
effect on the voltage-dependence of activation. It contains re-
peated rings composed of positively-charged amino acids followed
by two hydrophobic residues. This sequence is thought to form an
amphiphatic helix exposing positively-charged residues within the
membrane which act as voltage-sensors [10].
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Voltage-gated calcium channels
At least five types of voltage-gated calcium channels (termed L,
T, N, P and 0) have been distinguished by their electrophysiologi-
cal and pharmacological properties [reviewed in 2, 11]. For
example, L-type channels (L for long lasting) can be blocked by
the calcium channel antagonists 1,4-dihydropyridines, phenylalky-
lamines and benzothiazepines, but they are generally insensitive
to the peptide w-conotoxin.
The composition of the calcium channel was first obtained by
biochemical purification of L-type channels from transverse tubu-
lar membranes of rabbit skeletal muscle using dihydropyridines
[121. The channel consists of four distinct subunits: al (175 kD),
a2Th (175 kD), /3(52 kD) and y (32 kD). The components of the
channel complex associate specifically, as assessed by co-immu-
noprecipitation with monospecific antibodies and by co-sedimen-
tation in sucrose gradients, with a stoechiometric ratio of 1:1:1:1
for each subunit [reviewed in 5, 6]. All subunits of the skeletal
dihydropyridine L-type calcium channel were cloned and se-
quenced [13—17].
The al-subunit is in itself sufficient to form a functional calcium
channel as demonstrated by direct expression in Xenopus oocytes
and in mammalian L cells [18—21].
The contribution of the other subunits of the calcium channel
was determined by co-expression of the al-subunit with either /3-,
a2/- and y-subunits in Xenopus oocytes or mammalian cells
(CHO, HEK293 or L cells) [reviewed in 1, 2, 22, 23]. The
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Fig. 1. L-type calcium channel al-subunit structure. (A) Schematic representation of the al-subunit, and localization of the two predominant hypoPP
mutations. The al-subunit consists of four homologous repeats (domain Ito IV) containing six membrane spanning a-helices (Si to S6). The position
of the SS1 and SS2 segments implicated in ion selectivity of the channel are also shown. The positions of the two main mutations (arg528his, argl239his
or arg1239 gly) found in hypoPP families are also shown. These mutations are located in the fourth segment of the second and the fourth domain,
respectively. (B) Schematic representation of the tertiary structure of the al-subunit. Each homologous repeat (domain Ito IV) is located within the
membrane surrounding a central transmembrane pore.
magnitude of the calcium current expressed in these cellular
systems using the al-subunit was enhanced by co-expression of
the a2/b-subunit. The kinetic properties of the channel and of the
dihydropyridine binding site were also altered [18, 20, 24, 25].
Co-expression of the J3- and of the al-subunits increased the
calcium current directed by the al-subunit several-fold. The
13-subunit also accelerated both the activation and inactivation
kinetics of the calcium current [20, 24—291. Moreover, co-expres-
sion of the a2Ib- and 13- subunits to form a al/a21b113 complex,
dramatically enhanced the peak current, indicating considerable
synergism [20, 24].
A mammalian system which expresses only the auxiliary sub-
units, the muscular dysgenesis (mdg) mouse mutant, was used to
define the structural elements of the al-subunit necessary for
channel function in muscle [reviewed in 2, 23, 30]. This fatal
autosomal recessive mutation blocks the expression of the al-
subunit of the calcium channel, eliminating the L-type calcium
current, reducing intramembrane charge movement and suppress-
ing excitation-contraction coupling (E-C coupling) necessary for
the release of calcium from the sarcoplasmic reticulum [reviewed
in 31, 32]. Expression of the skeletal muscle al-subunit in mutant
cells rescues the mdg phenotype [33].
To identify the regions which determine the properties of the
al-subunit, chimeric subunits were constructed combining seg-
ments of skeletal and cardiac muscle al-subunits, and analyzed
for current waveform, calcium dependence of E-C coupling, and
intramembrane charge movement. The region implicated in E-C
coupling was identified as the large intracellular loop which
connects domains II and III [34]. The first domain (DI) contrib-
utes to the activation kinetic of the calcium channel [35]. Chimeric
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first domains (DI) constructed by substituting each transmem-
brane segment (Si to S6) of the skeletal domain with the cardiac
isoform, showed that the S3 segment and the linker connecting S3
and S4 in repeat I were responsible for the difference in activation
kinetics between cardiac and skeletal muscle L-type calcium
channels [36].
The molecular determinants of ion selectivity were also identi-
fied. In sodium and potassium channels, the SS1-SS2 region of the
S5-S6 linker region has been postulated to line the channel pore
and to play a major role in ion selectivity. In the calcium channel,
the S52 segment has also been implicated in ion selectivity, since
substitution of glutamate residues for lysinc in the SS2 segments
of the S5-S6 linker from regions I (DI) and III (DIII) altered
selectivity [37, 38]. Even a single amino acid change within the SS2
segment of the DIII and DIV domains transformed a sodium
channel into a calcium channel [39].
To identify the region of the calcium channel implicated in
dihydropyridine binding, chimeric calcium channels were con-
structed with al-subunits from L-type channels from cardiac
muscle, sensitive to dihydropyridines, and from brain, insensitive
to dihydropyridines, and were expressed in Xenopus oocytes. The
effects of dihydropyridine agonists and antagonists on these
chimeric proteins demonstrated that the linker between S5 and S6
in domain IV (DIV) of the L-type cardiac calcium channel was a
major site of dihydropyridine action [40].
The mechanism of inactivation of calcium channels has also
been extensively studied. The SS2-S6 region of domain III (DIII)
is important for inactivation [40]. Other studies showed that the
amino acids responsible for the kinetics of inactivation were
located in the membrane-spanning segment S6 of the first repeat
(DI), and the extracellular and cytoplasmic region flanking S6
[41]. The /3-subunits also play an important role in the inactivation
kinetics of calcium channels [reviewed in 1, 2, 22, 23]. A conserved
motif between repeats I and II which binds the /3-subunit was
recently identified [42]. Mutations within this motif (approximate-
ly 20 amino acids) reduced stimulation of peak currents by the
/3-subunit and altered the inactivation kinetics and the voltage-
dependence of activation.
Voltage-gated sodium channels
Pharmacological studies have demonstrated that mammalian
skeletal muscle expresses two types of sodium channels distin-
guished by their sensitivity to tetrodotoxin (TTX): the TTX-
sensitive sodium channel which is the adult isoform of the protein,
and the TTX-insensitive sodium channel which is expressed in
embryonic and denervated muscle, as well as in the heart [43—45].
The protein components of sodium channels were first identi-
fled by photoaffinity labeling with derivatives of a-scorpion toxins.
To determine the primary structure of sodium channels, sodium
channel a-subunit cDNAs from mammalian brain and muscle, as
well as from eel and Drosophila were cloned and sequenced
[reviewed in 8, 10]. All known sodium channels share a common
molecular structure. The primary sequence consists of 1800 to
2000 amino acids (260 kD) defining four large repeat domains
which exhibit internal homology at the amino acid level. Each of
these domains contain six regions capable of forming transmem-
brane helices designated Si to S6. There is more sequence
homology among the repeat domains within a given species than
between species, and low homology among interdomain regions,
except for interdomain III-IV. Interdomain Ill-TV contains a 53
amino acid sequence rich in lysines and arginines, hut with 4
prolines, allowing it to form a highly flexible charged element.
This is the shortest segment linking any of the repeat domains,
suggesting that domains III and IV may be physically coupled
[reviewed in 43] [44].
Complementary DNA clones encoding the /31-subunit of the rat
brain and skeletal muscle sodium channels were isolated. The
deduced primary structures indicated that the /31-subunit was a
protein of 23 kD containing a small cytoplasmic domain, a single
transmembrane segment and a large extracellular domain [1].
Expression of cloned a-subunits in Xenopus laevis oocytes
yielded functional sodium channels [46, 47]. Co-injection into
oocytes of mRNAs encoding domains I to III and mRNAs
encoding only the domain IV of the a-subunit suggested that all
four domains were required to form functional sodium channels
even when linkage between domains was interrupted [48]. Inac-
tivation was slower, however, in expressed a-subunits than in
neurons or muscle, and the voltage-dependence of inactivation
was shifted to more positive membrane potentials. Co-expression
of the a- and f31-subunits from rat brain or skeletal muscle in
oocytes accelerated inactivation, and shifted its voltage-depen-
dence to more negative membrane potentials [1]. The TFX
binding site located near the outer entrance of the channel
blocked ion flow either by physically occluding the channel or by
inducing a conformational change in the protein [45].
The role of the S4 helix as a voltage-sensor was first evaluated
by introducing point mutations into the S4 segment converting
positively charged amino acid residues into neutral or negatively-
charged residues [48]. A reduction in positive charges in segment
S4 of domain I decreased the slope of the voltage-dependence of
activation.
Inactivation of sodium channels is not strongly voltage-depen-
dent. The apparent voltage-dependence of inactivation is due to
the coupling of inactivation to voltage-dependent activation.
Studies using site-directed antibodies and site-directed mutagen-
esis in the interdomain III-IV indicate that this intracellular loop
is involved in inactivation [48, 49]. Slowed inactivation was
observed but effects on the voltage-dependence of the activation
or on the steady-state properties of inactivation were unremark-
able. Using alanine-scanning mutagenesis, it was suggested that
residues near the intracellular end of segment S6 of domain IV
play a role in fast sodium channel inactivation [50].
Hypokalemic periodic paralysis (hypoPP)
Familial periodic paralysis was recognized as a clinical entity as
early as the end of the nineteenth century. A decrease in blood
potassium levels during attacks of periodic paralysis was described
in 1934 by Biemond and Daniels [51], and founded the basis for
the first classification of periodic paralyses. A review of the earlier
literature concerning hypokalemic periodic paralysis (hypoPP) is
in [52—54]. The prevalence of hypoPP has been estimated to be
1/100,000. The disease is transmitted as an autosomal dominant
trait with reduced penetrance and expression in women. Women
may even escape expression of the phenotype, although they
transmit the disease. In consequence, a male to female predom-
inance of 3:1 has been reported [52]. We recently re-evaluated the
penetrance of hypoPP and found it to be 80% in women and
100% in men, in the families studied [55]. As in other dominant
diseases, new mutations have also been reported as well as
"sporadic" cases where there was no documented evidence of
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transmission to the descendance. The sporadic cases reported
were more frequently men than women. In light of the recent
findings, since the early cases lacked a molecular analysis, one may
suppose that some of these cases were actually familial, with
asymptomatic women in the genealogy, as we recently reported
[56].
The age of onset of hypoPP is within the second decade of life:
60% of patients develop the disease before the age of 16 [52],
although younger or later onsets have been reported.
The main provocative factors are rest after exercice and meals
rich in carbohydrates. Other factors include emotion, stress, cold
exposure and alcohol ingestion. Typical attacks occur at night and
the patient awakes paralyzed. The paralysis is flaccid, involving
the four limbs. Deglutition and ocular muscles are usually spared,
as is the diaphragm. The intercostal muscles may be affected,
however, resulting in difficult coughing and expectorating. Mild
attacks limited to the lower limbs or only to a group of muscles,
also occur. If attacks develop upon rest after exercice, they may be
aborted by pursuing a mild effort. Concomitant to the attack, a
decrease in blood potassium levels is observed due to movement
of potassium from the extracellular compartment into muscles.
There is no direct involvement of the heart, but modifications of
the electrocardiogram, directly related to the decrease in blood
potassium levels are observed. Blood potassium levels may fall to
1 mmol/liter. When the diagnosis is difficult, an attack may be
provoked by infusion of 2 g/kg of glucose and 0.1 unit/kg of
insulin. This test may induce profound hypokalemia and a severe
attack, and it should therefore be performed only under strict
medical supervision.
The frequency of attacks is variable. They are usually more
frequent in the second and third decade, and decline in frequency
as the patient gets older. Attacks may occur daily resulting in an
apparently permanent but reversible state of muscle weakness. An
attack may last from a few hours to a few days. Some patients may
only present a few attacks over their lifetime, or even a single
attack. Contrary to hyperPP, myotonic manifestations are never
observed, either clinically or by electromyography. Patients with a
lid-lag sign have been reported [57], but this sign is not specific to
myotonia and may be observed in normal individuals.
Independent of the severity and the frequency of periodic
paralysis attacks, and even in the absence of attacks, patients may
develop permanent muscle weakness due to vacuolar myopathy
[reviewed in 58]. This permanent muscle weakness should be
distinguished from subintrant attacks causing a prolonged but
reversible state of muscle weakness. The onset of the vacuolar
myopathy is usually in the fourth or fifth decade of life but cases
occurring as early as in childhood have been reported [59]. The
same morphological changes are evidenced in both hyper- and
hypokalemic periodic paralyses. They consist of a vacuolar myop-
athy first described by Goldflam in 1895 [60]. The vacuoles are not
specific to periodic paralysis and may be seen in the end-plate
myopathy of the slow-channel syndrome, and even in other muscle
disorders such as myotubular myopathy or polymyositis. Vacuoles
in muscle are now considered to reflect the myopathic process in
periodic paralysis even if occasional observations of vacuoles in
patients without a permanent muscle weakness, or cases with a
permanent muscle weakness and no vacuoles, have been reported
[reviewed in 58]. Vacuolar myopathy affects mostly the muscles of
the pelvic girdle and the proximal muscles of upper and lower
limbs. CT-scans demonstrate hypodense cores of the affected
muscles and replacement of the muscles by fat [61]. The origin of
the vacuoles has been debated. Since the work of Engel [58], the
vacuoles are considered to evolve from the sarcoplasmic reticulum
and the tubular system as the result of proliferation and degen-
eration of these membranous organelles. Consequently, there is
communication with the extracellular space as demonstrated by
the entry of extracellular peroxydase dye into the vacuoles [58].
The absence of correlations between the number and the
severity of attacks and the vacuolar myopathy, as well as the lack
of vacuoles at the onset of the disease, or in muscle fibers
rendered inexcitable [581, suggests that periodic paralysis attacks
and the vacuolar myopathy are two different phenotypes associ-
ated with an identical primary gene defect. Attacks represent a
highly penetrant phenotype contrary to the vacuolar myopathy
which is only observed in a third of the patients [58]. The factors,
genetic or epigenetic, triggering and controlling the expression of
these phenotypes are unknown. Other morphological changes are
also observed in periodic paralysis. Tubular aggregates, which are
proliferations of the lateral sacs on longitudinal components of
the sarcoplasmic reticulum, are localized under the sarcolemma.
Other changes include an increase in central nuclei, abnormal
variation in the fiber size, fiber necrosis and proliferation of
connective tissue elements.
Symptomatic treatment of hypoPP attacks by oral administra-
tion of potassium salts is usually sufficient. Severe attacks with a
profound hypokalemia may require intravenous infusion of potas-
sium salts under strict medical supervision in an intensive care
unit. Preventive measures include avoidance of the provocative
factors, and oral administration of potassium salts and acetazol-
amide [62].
HypoPP is a voltage-gated muscle calcium channel disorder
Electrophysiological studies performed in vitro on muscle fibers
from hypoPP patients revealed alterations in membrane excitabil-
ity. An unexpected observation concerned the reduction in the
resting membrane potential. Hypokalemia should, indeed, induce
membrane hyperpolarization instead of the observed depolariza-
tion. An increase in the permeability ratio NaIK was also
reported, and was mainly attributed to an elevated sodium
conductance (GN). The increase in GNa was not suppressed by
specific sodium channel blockers excluding, therefore, this ion
channel as the primary target in hypoPP [631. Nevertheless, these
observations pointed out to ion channels as possible clues in the
pathophysiology of the disease.
It was possible to profit from the existence of large families
affected by the disease and to use linkage studies to localize the
hypoPP gene. Given the electrophysiological data, the strategy
chosen for identifying the hypoPP gene was to localize the hypoPP
gene on the human genome, and to look for a known or an
unknown ion channel in the region [64, 65].
The initial linkage studies were conducted with three families of
Portuguese, German and French descent. Positive lod-scores were
observed for markers localized on chromosome 1q31 to 32,
establishing the hypoPP-1 locus [55]. The calcium channel al-
subunit CACNL1A3, also called the dihydropyridine receptor
(DHP receptor), mapped to the same region in the same 5 CM
interval as the hypoPP-1 locus [55]. Mutations were subsequently
found in the coding sequence of CACNL1A3, establishing it as
the hypoPP gene [66, 67]. Three mutations affecting two amino
acids contained within segment S4 were demonstrated. One
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replaces a positively charged arginine by a weakly-positive histi-
dine in position 528 in segment S4 of domain II (Fig. 1A). The
other two mutations replace an arginine by either a histidine or a
glycine in position 1239 in segment S4 of domain IV (Fig. 1A).
The two arginines affected by the hypoPP mutations belong to the
ring of positively-charged amino acids composing segment S4.
The role of these arginines is crucial, since it is conserved in the
primary structure of CACNL1A3 among different species and in
other members of the voltage-gated ion channel family. The
arg528his and argl239his mutations were found in a large number
of hypoPP families [66, 67]. In a series of 16 hypoPP families of
Caucasian origin, 8 presented the arg528his amino acid change,
and the other 8, the argl239his mutation [56]. The phenotype was
identical in terms of attacks and of the development of a vacuolar
myopathy. However, incomplete penetrance was observed only in
women with the arg528his mutation [561. Screening of these two
CACNL1A3 main mutations is therefore of diagnostic value in
hypoPP. Because of the incomplete penetrance of the arg528his
mutation, genotyping of all at-risk individuals, and especially
women, should be performed [56]. Characterization of the hap-
lotypes segregating with the mutations demonstrated that the
predominance of these two mutations was not due to a founder
effect, but to recurrent mutation. One hypoPP family, which was
also linked to chromosome 1q31 to 32, did not show either of the
two arginine mutations (unpublished data), suggesting that other
mutations in the calcium channel CACNLIA3 remain to be
discovered. Furthermore, although mutations in the CACNL1A3
gene are a major cause of hypoPP, at least two families with
hypoPP were not genetically linked to chromosome 1q31 to 32.
HypoPP is therefore genetically heterogeneous [681.
The amino acid changes observed in hypoPP result in an
autosomal dominant phenotype which suggest that both the
normal and the mutated allele are expressed. This is in contrast
with the mdg mutation which concerns the coding sequence of the
DHP receptor causing a shift in the translational reading frame
[69]. Consequently, no expression of the DHP receptor is ob-
served in skeletal muscles of homozygous mice. The mdg pheno-
type consists in neonatal death from respiratory arrest due to
complete paralysis of the skeletal muscle.
The skeletal muscle DHP receptor acts both as the L-type
calcium channel and as the voltage sensor for E-C coupling, but
does not play a key role in membrane excitation. Hence, genetic
linkage of hypoPP to the a-i subunit of the DHP receptor is
rather puzzling.
Recent analyses of the L-type calcium currents, recorded from
myotubes obtained from muscle biopsies of hypoPP patients,
revealed a shift in the steady state inactivation curve toward
negative potentials in the arg528his mutation, and a decrease in
the current density in the argl239his mutation. No alteration of
the voltage-dependent activation of the channel was found in
either mutation [70].
These findings do not provide a direct clue to the mechanism
underlying muscle paralysis, nor do they explain the abnormal
behavior of the sarcolemmal membrane of hypoPP patients.
Therefore, more thorough analyses of the DHP receptor dysfunc-
tion are currently undertaken. In addition, studies on the inter-
action of the mutated al-subunit with the other subunits of the
calcium channel are also underway, using in vitro expression
systems.
Triggering factors are necessary to produce an attack. Their
role is, however, more difficult to understand than in hyperPP (see
below). Exercise and meals rich in carbohydrates result in high
blood levels of adrenalin and insulin, both known to stimulate
sodium-potassium ATPase activity [71]. High pump activity may,
in turn, lead to hypokalemia. The pump is electrogenic, and
makes a slight contribution to the resting membrane potential.
However, the potential Ep, brought by the pump is directly
related to membrane resistance by Ohm law. Hence, when the
membrane is depolarized, its resistance drops, and Ep becomes
negligible.
A difficult task is to understand how hypokalemia interacts with
the mutated channel to lead to muscle depolarization and paral-
ysis. The link between channel mutation and muscle disorders
may involve changes in the expression and/or function of other
ionic channels and cellular processes contributing to membrane
excitability.
Expression of the mutated channel in muscle cells might also
give insight into the processes underlying vacuolar myopathy. In
the mouse mdg mutant, the absence of expression of the dihydro-
pyridine receptor results in disorganization of the triads which are
membranous formations coupling the T-tubular system to the
sarcoplasmic reticulum. As described above, vacuoles arise from
the T-tubular system and the sarcoplasmic reticulum. Their
occurrence could be investigated by following the formation of the
T-tubular system and the sarcoplasmic reticulum in developing
muscle cells transfected with the mutated calcium channel gene.
Thyrotoxic hypoPP is another type of hypoPP. Unlike familial
hypoPP, thyrotoxic hypoPP occurs sporadically in 95% of cases.
Thyrotoxic hypoPP is 70 times more common in males than in
females, and affects Orientals in 75% of cases. In hyperthyroid
Chinese, the risk of developing the disease is 15 to 20%. Clinical
manifestations are similar to familial hypoPP and cease when the
euthyroid state is restored. The dihydropyridine receptor, may
also account for the pathophysiology of thyrotoxic hypoPP. Thy-
roid hormones stimulate the sodium-potassium pump ATPase,
and could, thereby, induce hypokalemia. Susceptible persons in
the Oriental population might carry a dihydropyridine receptor
allele, insufficient by itself to confer hypoPP, but able, in a
hyperthyroid state, to cause thyrotoxic hypoPP. This hypothesis is
theoretically testable by characterizing dihydropyridine receptor
alleles in a population with thyrotoxic hypoPP.
Hyperkalemic periodic paralysis (hyperPP)
The complete description of Hyperkalemic periodic paralysis(hyperPP) is credited to Gamstorp [72], but Tyler and his
collaborators also reported a similar family [73]. HyperPP is a
muscle disorder of genetic origin transmitted with an autosomal
mode of inheritance. The penetrance is high, close to 100%.
Sporadic cases and neo-mutations also occur, although the ma-
jority of patients belong to families displaying the trait. The
prevalence of the disease is not known. Patients with hyperPP
present acute attacks of muscle weakness accompanied by an
increase in blood potassium levels. The age of onset is usually in
the first years of life, before the patient begins to walk. The
frequency of attacks is variable, ranging from one every month to
several per week. The duration of attacks is also variable, from 10
minutes to two hours. Attacks most often affect the lower limbs,
and sometimes the upper limbs. The muscles of the head and neck
are usually spared as well as the diaphragm. Besides these classical
manifestations, attacks may be atypical by the length of duration
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Table 1. Mutations in the muscle sodium channel and their corresponding phenotype
Phenotype Mutation Channel part Substitution Electrophysiology References
HyperPP C2188T DIIS5 Thr7O4Met Abnormal inactivation
NormoPP Shift in the voltage-dependence
of activation
[86, 101, 102]
HyperPP G3466A DI1IS4/S5 Alall56Thr Abnormal inactivation [88, 103]
PC
HyperPP A4078G DIVS1 Metl36OVal nd [94]
HyperPP A4774G DIVS6 Metl592Val Abnormal inactivation [87, 102]
SCM C2411T DIIS6 Ser804Met nd [88]
SCM (acetazo lamide- A3555G DIIIS4/S5 Ilell6OVal nd [95]
responsive)
PC/SCM G3917T Dill-DIV Glyl3O6Val Abnormal inactivation [89, 921
SCM G3917A Dill-DIV Glyl3O6Glu Abnormal inactivation [92]
SCM G3917C Dill-DIV Glyi3O6Ala Abnormal inactivation [92]
PC/SCM C3938T Dill-DIV Thrl3l3Met Abnormal inactivation [89, 103]
PC T4298G DIVS3 Leul433Arg Abnormal inactivation [93, 103]
PC C4342T DIVS4 Argl448Cys Abnormal inactivation [90, 103, 104]
PC C4343A DIVS4 Argl448flis Abnormal inactivation [90, 103, 104]
SCM G4765A DIVS6 Vall589Met Abnormal inactivation [91, 105]
DI to DIV and Si to S6 indicate the domains and the segments of the sodium channel, respectively. Abbreviations are: HyperPP, hyperkalemic
periodic paralysis; NormoPP, normokalemic periodic paralysis; PC, paramyotonia congenita; SCM, sodium channel myotonia. Original references are
cited.
(several days to months), their location in a single limb, the
involvement of head and neck muscles or the diaphragm. Attacks
occur when resting after exercice, and may be aborted by resum-
ing the exercise. Attacks may be provoked by a meal low in
carbohydrates or by cooling the muscles.
Myotonic manifestations are frequently observed in hyperPP
patients. Myotonia is caused by a prolonged failure of muscle
decontraction. It is characterized by high-frequency repetitive
discharges of sarcolemmal membrane producing a "dive-bomber"
sound on the audio-monitor during recording by electromyogra-
phy. "True" myotonia is ameliorated by repetitive movements, the
so-called "warm-up phenomena," whereas paramyotonia or "par-
adoxical myotonia" worsens during exercice. Contraty to the attacks,
myotonic manifestations may be more constant and therefore of
importance for the diagnosis. The patient may present cramps or
muscle stiffness during exercice or when exposed to cold. The
most frequent clinical myotonic manifestation is in the eyelids.
Percussion myotonia is usually not encountered. In hyperPP
patients with the same known genetic defect, clinical manifesta-
tions of myotonia were present in 25% of cases, and typical
electromyographic signs in 50% of cases [74]. A diagnosis of
hyperPP should, therefore, be considered in a patient presenting
periodic paralysis with myotonia, and the diagnosis of hypoPP
regarded as unlikely. The absence of myotonia does not, however,
exclude the diagnosis. Hyperkalemia is usually mild and does not
induce cardiac dysrhythmia. In patients with the same known
genetic defect, hyperkalemia was only demonstrated in 50% of
patients even when repeated measurements of blood potassium
levels were performed during the attacks [741. Normokalemic
periodic paralysis and hyperPP are in fact the same clinical and
genetic entity. Later in life, patients develop a vacuolar myopathy
which cannot be distinguished from that observed in hypoPP [75].
Clinical variants of hyperPP have been described. The most
notable syndrome is hyperPP with paramyotonia [76, 771. Co-
segregation of both disorders in same families led to the hypoth-
esis that hyperPP and paramyotonia congenita (PC) were allelic
disorders. PC was described last century as a myotonic syndrome
of autosomal dominant inheritance [781. Paramyotonia was dif-
ferentiated from myotonia congenita which is now known to be a
chloride channel disorder [79, 80]. Contrary to myotonia con-
genita, where a warm-up phenomenon is observed, the myotonia
in paramyotonia is aggravated by exercise. Furthermore, PC
patients present muscle stiffness and weakness induced by cold.
Symptoms may also be provoked by ingestion of potassium salts as
observed in hyperPP. However, contrary to hyperPP, vacuolar
myopathy is never observed in PC.
In hyperPP, successful prevention is most frequently obtained
by frequent meals of high carbohydrate content and avoidance of
fasting, exposure to cold, or overexertion. If these precautions are
not sufficient, diuretic agents such as acetazolamide or thiazides
are usually effective in the prevention of attacks of muscle
weakness.
HyperPP is a voltage-gated muscle sodium channel disorder
The clue to identify the hyperPP gene was reported by Leh-
mann-Horn and collaborators [81], who observed the occurrence
of non-inactivating sodium currents in muscle fibers from hyperPP
patients, when the extracellular potassium concentration was
increased. These results provided strong arguments for the impli-
cation of abnormal sodium channels in hyperPP [811. Following
the characterization of the rodent muscle sodium channel gene
[44], the human equivalent was isolated and a polymorphism was
found, enabling linkage analysis [82]. Co-segregation of the
sodium channel was first observed in a large family with hyperPP,
suggesting that the primary defect resided in the sodium channel
gene [82]. Similar observations were made in hyperPP families of
other ethnic backgrounds, as well as in PC families, demonstrating
that hyperPP and PC were allelic disorders [83—85]. Mutations
were found in the coding sequence of the sodium channel gene
establishing it as the hyperPP gene [86, 87]. To date, fourteen
point mutations have been found in the human sodium channel
gene [86—951. Table 1 summarizes these mutations and the
genotype/phenotype correlations. Two of the mutations causing
hyperPP, Thr7O4Met and Metl592Val [74, 95, 96], account for
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approximately 75% and 25% of the hyperPP families studied,
respectively [74, 95, 961. No founder effect could be demonstrated
by characterization of the haplotypes segregating with mutations
[74, 96]. As shown in Table 1, the variety of mutations is greater
in PC than in hyperPP [93]. The Thrl3l3Met mutation was found
in a majority of French families [74]. No founder effect was
demonstrable, however, arguing in favor of recurrent mutations in
the sodium channel gene [74, 97]. A founder effect for PC could
only be demonstrated for an unusual cluster of families originat-
ing in the Ravensberg area of Germany [98]. Genetic and
molecular analysis of the sodium channel permitted re-evaluation
of families displaying autosomal dominant myotonic syndromes
resembling myotonia congenita caused by a chloride channel
defect. A myotonic syndrome either termed "acetazolamide-
responsive myotonia congenita" or "sodium channel myotonia
(SCM)" has therefore been added to the list of sodium channel
muscle disorders [95, 99].
HyperPP also affects Quarter horses. The mutation has been
disseminated by selective breeding among approximately 5% of
the Quarter horse population [100]. Genetic linkage to the
sodium channel gene has been demonstrated, and a point muta-
tion was found that changes amino acid 1410 from a phenylala-
nine to a leucine located in segment 3 of domain IV of the sodium
channel [100].
To investigate the dysfunction of mutated channels, in vitro
expression studies were conducted. The Thr7O4Met and the
Metl592Val mutations were introduced into the rat skeletal
muscle channel which was then expressed in a human embryonic
kidney cell line [101, 102]. Both mutations disrupted inactivation
without affecting single channel conductance. The Thr7O4Met
mutation caused late first opening, prolonged open times and a
negative shift in the voltage-dependence of activation [101].
Neither of the mutant channels were sensitive to increases in
extraeellular potassium. Cummins and collaborators thought that
the hyperpolarizing shift in the voltage-dependence of activation
was the most important effect [101], while Cannon and Strittmat-
ter put an emphasis on the magnitude of the sodium influx [102].
Mutations identified in PC and SCM patients have been intro-
duced either in rat or human skeletal muscle sodium channel gene
and expressed in different cell types. The mutants ArgI 448Cys,
Argll48His, AlallS6Thr, Thrl3l3Met, Leul433Arg, Glyl3O6AJa,
Glyl3O6Glu, Glyl3O6Val and Vall589Met similarly disturbed
channel inactivation, and altered voltage-dependence [91, 102—
105]. Neither the Argl448Cys, Argl448His, Ala1l56Thr, Thr1313
M or Leul433Arg mutants affected the activation. Analysis of
single channel recordings revealed that Argl448Cys and
Argl448His mutant channels inactivated normally from closed
states, but poorly from the open state [104]. How do these
observations compare with the in vivo situation? Single channel
recordings from muscle biopsies of patients clearly demonstrated
abnormal inactivation of the sodium channel in hyperPP [106,
107]. In contrast to normal muscle, the proportion of non-
inactivating channels increased to 3 to 5% in high potassium
concentration [106, 107].
How might a periodic paralysis attack occur? An increase in
extraeellular potassium induces membrane depolarization. Even a
slight depolarization may be sufficient to activate mutated chan-
nels characterized by low activation voltage threshold. Non-
inactivating sodium current will develop and lead to sustained
membrane depolarization. This will result in the inactivation of
normal sodium channels, thereby impairing the main key for
membrane excitation.
Periods of hyperexeitability and myotonia could be explained by
the fine balance between the extent of membrane depolarization
determined by the opening of mutated sodium channels, and the
efficiency of membrane repolarization due to potassium outfiux.
Large depolarizations would lead inevitably to membrane inexeit-
ability. Limited depolarization could still allow normal sodium
channels to reactivate and support, for limited periods, repetitive
action potentials.
The return to the resting membrane potential and the end of
the paralysis attack may be explained by an increase in the
sodium-potassium ATPase activity. This effect would be triggered
by the accumulated changes in the sodium and potassium gradi-
ents. Consistent with a restoration in the ion balance, a polyurie
crisis is often observed at the end of an attack.
High sodium-potassium pump activity may also intervene for
preventing the attacks. According to Lehmann-Horn and collab-
orators [54], interruption of paralysis attacks by mild exereiee may
be due to the stimulation of the sodium-potassium pump by
adrenaline and acidosis. The attacks will then only occur after rest
[71]. For the same reason, the protective effect of acetazolamide
might also be due to the induction of long-term acidosis. Fasting
is also a provocative factor in hyperPP. It is known to decrease
insulin secretion, thereby diminishing the protective effect of high
sodium-potassium ATPase activity.
Conclusion
In the past few years, periodic paralyses were shown to be due
to mutations in muscle voltage-gated ion channels. Hypokalemie
and hyperkalemie periodic paralysis are diseases of calcium and
sodium channels, respectively. These mutations are not lethal,
causing only subtle effects on channel behavior. Analysis of the
dysfunction of these natural mutations, which affect regions not
previously investigated by in vitro mutagenesis, has already in-
creased our knowledge on the mechanism of sodium channel
inactivation. The understanding of the complete disease pheno-
types is, however, far from complete. The bases of the modifica-
tions of blood potassium levels and of the vaeuolar myopathy are
still unknown. The mechanism underlying vacuolar myopathy
might be elucidated by studies of the effect of mutated channels
on the development and the physiology of the tubulo-reticular
system in muscle. Co-expression studies with mutated channels,
other channel subunits or other ion channels should help to
understand the disease phenotypes as well as the interactions
between ion channels. They will also help to develop effective
drug therapies.
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